Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trialResearch in context

Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trialResearch in context

Summary: Background: Pediatric patients with certain rare diseases are at increased risk of severe respiratory syncytial virus (RSV) infection. However, the prophylactic use of anti-RSV antibody (palivizumab) in these patients is not indicated at present in Japan. Methods: This first-in-the-world m...

Full description

Bibliographic Details
Main Authors: Masaaki Mori, Kanako Yoshizaki, Shinichi Watabe, Mika Ishige, Akinari Hinoki, Takuya Kondo, Tomoaki Taguchi, Hisaya Hasegawa, Tomoko Hatata, Naoyuki Tanuma, Kosuke Kirino, Akihiro Hirakawa, Takuya Naruto, Minoru Imai, Ryuji Koike, Kenichiro Hosoi, Satoshi Kusuda
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:The Lancet Regional Health. Western Pacific
Subjects:
Airway stenosis
Congenital esophageal atresia
Efficacy
Inherited metabolic disease
Neuromuscular disease
Palivizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2666606523001657

Internet

http://www.sciencedirect.com/science/article/pii/S2666606523001657

Similar Items